Advancing Precision Medicine: Biomarker Discovery for Complex Diseases
.jpg)
Biomarker discovery is revolutionising complex disease management in Asia, addressing rising cancer and neurodegenerative disease burdens. AI-driven multi-omics and liquid biopsies enable early detection and personalised therapies. Despite regulatory challenges, Asia's precision medicine initiatives are advancing, promising improved outcomes for diverse populations by 2025.
Introduction
Precision medicine represents a paradigm shift from one-size-fits-all treatments to tailored interventions based on individual genetic, environmental, and lifestyle factors. At its core lies biomarker discovery, identifying measurable indicators of disease presence, progression, or response to therapy. Complex diseases, such as cancer, autoimmune rheumatic disorders, and rare genetic conditions, pose unique challenges due to their multifactorial nature. Traditional approaches often fall short in capturing this complexity, but recent advancements in integrative analysis and artificial intelligence (AI) are bridging the gap.
The integration of multi-omics data, genomics, transcriptomics, proteomics, and more, allows for a systems-level understanding of disease mechanisms. Projects such as The Cancer Genome Atlas (TCGA) and the Alzheimer's Disease Neuroimaging Initiative (ADNI) exemplify this, revealing novel biomarkers through the fusion of large-scale data. AI, particularly machine learning (ML) and deep learning (DL), amplifies these efforts by uncovering hidden patterns in vast datasets. For instance, AI models predict drug sensitivity, immune responses, and disease trajectories with unprecedented accuracy.
This editorial synthesises insights from key references, including editorial overviews on integrative analysis, AI applications in health records and immunology, and AI-driven biomarker discovery in oncology. It also incorporates ML for rare genetic disorders, AI in immunogenomics and radiomics, multi-omics integration, and emerging AI methodologies. By examining these, we highlight how biomarker discovery is advancing precision medicine, while addressing ethical and practical hurdles.
Integrative Analysis in Biomarker Discovery
Integrative analysis combines diverse data sources to identify robust biomarkers for complex diseases. Traditional single-omics approaches are limited, but multi-omics integration reveals interconnected pathways and molecular signatures.
A recent editorial on integrative analysis for complex disease biomarker discovery emphasises this shift. It discusses how multi-omics data from genomics, epigenomics, and proteomics enable predictive modelling. For fetal growth restriction (FGR), miRNA-mRNA analysis identified the Smad2/miR-155-5p axis as a key biomarker, suggesting therapeutic targets. In cancer, DL and similarity network fusion predict drug sensitivity by fusing omics layers, reducing overfitting and enhancing precision oncology.
Similarly, the TCGA project analysed over 20,000 cancer samples across 33 types, uncovering biomarkers like mutated genes and immune profiles. ADNI integrates genomics with imaging to develop Alzheimer's biomarkers, demonstrating how systems-level views enhance prognosis.
Machine learning enhances integration. In rare genetic disorders, ML tailors treatments to individual genomes, enabling accurate diagnoses and risk assessments. Algorithms process high-dimensional data to identify variants associated with disease phenotypes, accelerating biomarker validation.
These approaches build single or hybrid predictive models. For instance, a 21-gene signature in breast cancer predicts myeloid-derived suppressor cell infiltration, which is linked to epithelial-mesenchymal transition. Such discoveries underscore integrative analysis in uncovering biomarkers that traditional methods miss.
AI-Driven Approaches for Biomarker Identification
AI is revolutionising biomarker discovery by handling data volume, variety, and velocity. ML and DL models excel at pattern recognition, variant calling, and multi-modal integration.
In oncology, AI integrates health records, genetics, and immunology for personalised insights. Electronic health records (EHRs) are processed through steps like data collection, cleaning, and normalisation, enabling ML to predict disease activity and optimise therapies. Deep learning analyses genomic variants, MHC-peptide binding, and immune responses, identifying biomarkers for autoimmune diseases like rheumatoid arthritis.
A review on AI-driven biomarker discovery highlights its precision in cancer diagnosis and prognosis. DL decodes tumor biopsies and blood tests to find survival-linked biomarkers. Some platforms use bioinformatics to mine multimodal omics for therapeutic targets. AI frameworks improve interpretability, as seen in NSCLC models that link biomarkers to outcomes.
For rare disorders, ML enhances genome-based precision medicine. It enables customised treatments by analysing genetic overviews, addressing data scarcity through advanced algorithms.
Emerging tools focus on immunogenomics, radiomics, and pathomics. In immunogenomics, AI analyses single-cell RNA sequencing (scRNA-Seq) to identify biomarkers like DUSP4 and LAIR2 for T-cell exhaustion. Radiomics extracts imaging features from CT/MRI to predict PD-L1 expression and tumor mutational burden (TMB), achieving high AUC values (e.g., 0.905). Pathomics uses DL on pathology images to uncover spatial biomarkers, such as T-cell colocalization, predicting immunotherapy responses.
Multi-omics integration via DL models fuses data for comprehensive biomarker panels. Bayesian methods and ensemble learning handle uncertainty, as in cancer prognosis models.
These AI approaches not only discover biomarkers but also predict responses, exemplified by models forecasting immunotherapy efficacy in lung cancer.
Applications in Specific Complex Diseases
Biomarker discovery's impact is evident in cancer, autoimmune disorders, and rare genetic conditions.
In cancer, AI uncovers prognostic biomarkers. For breast cancer, pathomics predicts immune checkpoint proteins with an AUC of 0.601–0.864. In NSCLC, XAI identifies signatures for early detection. Integrative analysis in pancreatic cancer uses ML to predict survival, integrating radiomics with clinical data.
Autoimmune rheumatic diseases benefit from AI-integrated EHRs and immunology. ML classifies antinuclear antibody patterns and predicts adalimumab immunogenicity in rheumatoid arthritis. A 21-gene signature forecasts myeloid cell infiltration in luminal a breast cancer, applicable to autoimmune contexts.
Rare genetic disorders leverage ML for variant prioritisation. In conditions like osteosarcoma, ML models predict survival using SEER data. For FGR, miRNA axes serve as biomarkers.
Joint capsule fibrosis studies show platelet-rich plasma attenuates fibrosis via TGF-β1/Smad signalling validated through integrative omics. These applications demonstrate AI's role in translating biomarkers into clinical tools, improving outcomes in precision oncology and beyond.
Challenges and Future Directions
Despite progress, challenges persist. Data quality, heterogeneity, and small sample sizes lead to overfitting. Ethical issues include privacy, bias, and algorithmic transparency. Diverse populations are underrepresented, risking health disparities.
Interpretability is key; AI addresses "black box" concerns. Regulatory frameworks must evolve for AI validation in trials.
Future directions include multimodal AI integration, combining immunogenomics with radiomics for holistic biomarkers. Federated learning could mitigate privacy issues while enabling large-scale analysis. Continued validation through experimental studies and clinical trials is essential.
Advancements in Bayesian ML for uncertainty handling and DL for single-cell data will refine predictions. Ultimately, these will accelerate precision medicine, reducing morbidity in complex diseases.
Conclusion
Biomarker discovery via integrative analysis and AI is propelling precision medicine forward. From multi-omics fusion in cancer to ML for rare disorders, these tools enable early diagnosis, targeted therapies, and improved prognoses. While challenges like data privacy and bias remain, the potential to personalize care is immense. As AI evolves, it promises to democratize precision medicine, enhancing global health equity.
References:
- Advancing precision medicine: the transformative role of artificial intelligence in immunogenomics, radiomics, and pathomics for biomarker discovery and immunotherapy optimization. Cancer Biol Med. 2025. https://www.cancerbiomed.org/content/early/2025/01/06/j.issn.2095-3941.2024.0376
- Advancing genome-based precision medicine: a review on machine learning applications for rare genetic disorders. Brief Bioinform. 2025;bbaf329. https://academic.oup.com/bib/article/doi/10.1093/bib/bbaf329/8203342
- Editorial: Integrative analysis for complex disease biomarker discovery. Front Bioeng Biotechnol. 2023;11:1273084. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10476627/
- Unlocking precision medicine: clinical applications of integrating health records, genetics, and immunology through artificial intelligence. J Biomed Sci. 2025;32:16. https://jbiomedsci.biomedcentral.com/articles/10.1186/s12929-024-01110-w
- AI-driven biomarker discovery: enhancing precision in cancer diagnosis and prognosis. Discov Oncol. 2025;16:313. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11906928/
- AI-driven multi-omics integration for biomarker discovery in complex diseases. J Biol Methods. 2025. https://linkinghub.elsevier.com/retrieve/pii/S2950194625001360
- Deep learning for multi-omics integration in biomarker discovery. NAR Genom Bioinform. 2022;lqaf038. https://academic.oup.com/nargab/article/doi/10.1093/nargab/lqaf038/8124945
Dr. Vaishnavi Rathod
